Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19122669 | 0.84 | HTR2A (0.43) | ADRA1ATAAR1HTR2AMTNR1AMTNR1B | |
| SCHEMBL6491986 | 0.83 | TNKS2 (0.44) | ADRA1ATAAR1MTNR1AMTNR1BAOC3 | |
| SCHEMBL18304711 | 0.82 | HTR2A (0.40) | ADRA1ATAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL3360173 | 0.81 | ADRA1A (0.40) | ADRA1ATAAR1HTR2AMTNR1AMTNR1B | |
| SCHEMBL7782798 | 0.80 | GABRA1 (0.48) | ADRA1ATAAR1HTR2AAOC3 | |
| SCHEMBL13845991 | 0.80 | ADRA1A (0.39) | ADRA1ATAAR1HTR2AMTNR1AMTNR1B | |
| SCHEMBL13845938 | 0.80 | ADRA1A (0.39) | ADRA1ATAAR1HTR2AMTNR1AMTNR1B | |
| SCHEMBL13845934 | 0.80 | ADRA1A (0.39) | ADRA1ATAAR1HTR2AMTNR1AMTNR1B | |
| SCHEMBL6853537 | 0.79 | HTR2A (0.50) | TAAR1HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL6488953 | 0.79 | SLC6A4 (0.50) | HTR2AHTR2CHTR2BAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | MAPK3, MAPK1, MAPKAPK3 | ADRA1A 1832/4885TAAR1 2654/4885HTR2A 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.